SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that management will present at two upcoming
investment conferences:
- H.C. Wainwright 21st Annual Global Investment
Conference on Tuesday, September
10 at 4:40 p.m. Eastern time.
The conference is being held at the Lotte New York Palace
Hotel;
- Fall Investor Summit on Tuesday,
September 17 at 9:30 a.m. Eastern
time at The Essex House in New
York City.
A live webcast and replay of the presentation at the H.C.
Wainwright Global Investment Conference will be available on the
Company's website at http://ir.biocept.com/. A replay of the
presentation will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-two-investment-conferences-in-september-300908220.html
SOURCE Biocept, Inc.